|
Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Within I.V. generic drugs, Fresenius Kabi counts among the leading suppliers in the U.S. market.
We are focused on the therapy and care of critically and chronically ill patients in and outside the hospital.
Fresenius Kabi has more than 22,500 employees worldwide and a global network of more than 60 production sites and compounding centres. In 2010, Fresenius Kabi sales were € 3,672 million and the companys EBIT was € 737 million.
Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE & Co. KGaA.
Key Figures
| €m | 2010 | 2009 | Change |
 | | | |
| Sales | 3,672 | 3,086 | 19 % |
| EBITDA | 893 | 742 | 20 % |
| EBIT | 737 | 607 | 21 % |
| Net Income* | 294 | 200 | 47 % |
| Employees | 22,851 | 21,872 | 4 % |
| | | |
*Net income attributable to Fresenius Kabi AG. | 
